Michael Khan adds voice to Silence board
This article was originally published in Scrip
RNAi therapeutics company Silence Therapeutics has appointed Dr Michael Khan to its board of directors as chief medical advisor. Dr Khan is an associate professor of medicine at the UK's University of Warwick and a consultant physician at University Hospitals.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.